Skip to main content
. 2022 Apr 13;14(8):1949. doi: 10.3390/cancers14081949

Table 3.

Disease-free survival (DFS) and overall survival (OS) in early-stage NSCLC with KRAS expression.

Study Year Kind of Study Patients (Total/K-Ras) Stage DFS OS
Nelson et al. 1999 Prospective 365 (44) I–IV n.r.* negative
Lu et al. 2004 Retrospective 94 (34) I n.s. n.s.
Lin M-W et al. 2014 Retrospective 64 (4) I (syn) n.s. n.s.

* n.r.: not reported. n.s.: not significant.